Claim Ledger
88% answered
Did management answer the analysts?
12 analyst questions audited.
View Claim Ledger →
Alkem Laboratories Ltd — Q3 FY26
Alkem delivered a stable Q3 with total revenue of ₹3,737 crore (+10.7% YoY) and EBITDA margin of 22.2%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem delivered a stable Q3 with total revenue of ₹3,737 crore (+10.7% YoY) and EBITDA margin of 22.2%. Domestic business grew 5.5% reported but ~10% on a normalized basis, driven by strong chronic portfolio and market share gains across six therapies. International sales surged 26.6% YoY to ₹1,216 crore. The highlight was the announcement of a 55% stake acquisition in Occlutech, a structural heart medtech company, for ~₹1,100 crore, with plans to scale revenue to ₹1,000 crore in 3-5 years and improve EBITDA margins from 4% to 25%. Management reiterated full-year guidance and bullish outlook. Key risk: MIP on penicillin derivatives could impact gross margins by 50-100 bps, though inventory and pricing actions may mitigate.
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
MIP on penicillin derivatives impacting gross margins
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic Business YTD Growth
10%
+10pp YoY
Domestic business grew ~10% YTD, with core branded generic growing 11-12%, outperforming IPM.
International Sales Growth
26.6%
+26.6pp YoY
International sales grew 26.6% YoY to ₹1,216 crore, driven by strong performance in US and other markets.
Occlutech Revenue Target (CY26)
₹600 crore
N/A
Occlutech expected to generate ~₹600 crore revenue in CY26, growing at 14% CAGR over 5 years.
Occlutech Gross Margin
73%
N/A
Occlutech's gross margin is ~73%, with potential for expansion via product mix and operating leverage.
What Changed vs Last Quarter
NEW
Occlutech EBITDA margin to reach 25% in 3-5 years
Occlutech's EBITDA margin is expected to improve from current ~4% to 25% in 3-5 years, driven by operating leverage and product mix.
NEW
Occlutech revenue CAGR of 14% over 5 years
Occlutech is expected to grow at 14% CAGR over the next 5 years, reaching ~₹780 crore, excluding new products.
NEW
Denosumab US entry by end of FY26
Denosumab US launch expected by end of FY26, pending FDA inspection and litigation resolution.
UPDATED
Domestic business to grow 100-150 bps above IPM
Management expects domestic business to continue growing 100-150 bps above IPM growth, with FY26 ending at ~10% growth.
DROPPED
Full-year EBITDA margin guidance of 19.5-20%
Despite H2 opex from US CDMO (~₹50-60 cr/quarter) and GST impact (~₹50-60 cr), management expects EBITDA margin of 19.5-20% for FY26.
DROPPED
US CDMO plant to reach ₹300 cr annual revenue in 12-18 months
The US CDMO plant, operational from September, is expected to achieve an annual run-rate of ₹300 crore within 12-18 months.
DROPPED
R&D spend to be 4-5% of revenue for FY26
R&D expenses were 3.3% in H1; management expects full-year R&D to be within 4-5% due to phasing of filings in Q4.
NEW RISK
MIP on penicillin derivatives impacting gross margins
The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.
NEW RISK
Occlutech integration and execution risk
Occlutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.
NEW RISK
Denosumab litigation delay
US entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.
NEW RISK
Trade generic business headwinds
Trade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth.
RISK GONE
Price erosion in US generics
Sacubitril launch faces competitive pricing pressure; price erosion could impact US revenue growth in subsequent quarters.
RISK GONE
GST impact on margins
GST revision will reduce benefits from Sikkim facility, causing a ₹50-60 crore impact in H2, pressuring margins.
RISK GONE
US CDMO ramp-up and breakeven timeline
CDMO plant opex of ₹50 cr/quarter with only ₹20 cr revenue initially; breakeven expected in 12-18 months, but delays could weigh on profitability.
RISK GONE
Penicillin G MIP uncertainty
Government may impose minimum import price on Penicillin G; management declined to comment, citing speculation, but it could increase costs.
🤫 Topics management stopped discussing
Mentioned in Q1 FY26, Q2 FY26
Despite H2 opex from US CDMO (~₹50-60 cr/quarter) and GST impact (~₹50-60 cr), management expects EBITDA margin of 19.5-20% for FY26.
Mentioned in Q1 FY26, Q2 FY26
Sacubitril launch faces competitive pricing pressure; price erosion could impact US revenue growth in subsequent quarters.
Mentioned in Q1 FY26, Q2 FY26
R&D expenses were 3.3% in H1; management expects full-year R&D to be within 4-5% due to phasing of filings in Q4.
Fast read
Guidance and risk preview
Management expects domestic business to continue growing 100-150 bps above IPM growth, with FY26 ending at ~10% growth.
The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions...
View Risks →